Zurich based CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue

blonca9
Sep 23, 2024
1 min read

Co-Founder & CEO Christian Leisner describes the M-gager platform and how it allows the company to have high specificity to targets, and even go after intracellular antigens displayed as small HLA peptides.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Zurich based CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight